- Home
- CSTE vs ESLA Comparison
CSTE vs ESLA Comparison
Compare CSTE & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSTE | ESLA |
|---|---|---|
| Founded | 1987 | 2021 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.7M | 69.5M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | CSTE | ESLA |
|---|---|---|
| Price | $1.78 | $1.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 163.0K | 30.2K |
| Earning Date | 05-13-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.43 | N/A |
| Revenue Next Year | $2.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $0.78 |
| 52 Week High | $2.58 | $3.15 |
Technical Indicators
Market Signals| Indicator | CSTE | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 53.76 | 39.07 |
| Support Level | $1.42 | $1.00 |
| Resistance Level | $1.76 | $1.31 |
| Average True Range (ATR) | 0.12 | 0.11 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 19.74 | 22.73 |
Price Performance
Historical ComparisonAbout CSTE Caesarstone Ltd.
Caesarstone Ltd manufactures engineered quartz surfaces. Its products include engineered quartz and porcelain slabs, which are used as kitchen countertops in renovation and remodeling, and residential construction. It also has other applications, including vanity tops, wall panels, backsplashes, floor tiles, stairs, and other interior surfaces that are used in various residential and non-residential applications. The company sells its products under the Caesarstone brand. Caesarstone's geographical segments are the United States, Canada, Latin America, Australia, Asia, Israel, and EMEA(Europe, Middle East, Africa), of which it derives maximum revenue from United States.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.